Ontology highlight
ABSTRACT:
SUBMITTER: Rawstron AC
PROVIDER: S-EPMC4832072 | biostudies-literature | 2016 Apr
REPOSITORIES: biostudies-literature
Rawstron A C AC Fazi C C Agathangelidis A A Villamor N N Letestu R R Nomdedeu J J Palacio C C Stehlikova O O Kreuzer K-A KA Liptrot S S O'Brien D D de Tute R M RM Marinov I I Hauwel M M Spacek M M Dobber J J Kater A P AP Gambell P P Soosapilla A A Lozanski G G Brachtl G G Lin K K Boysen J J Hanson C C Jorgensen J L JL Stetler-Stevenson M M Yuan C C Broome H E HE Rassenti L L Craig F F Delgado J J Moreno C C Bosch F F Egle A A Doubek M M Pospisilova S S Mulligan S S Westerman D D Sanders C M CM Emerson R R Robins H S HS Kirsch I I Shanafelt T T Pettitt A A Kipps T J TJ Wierda W G WG Cymbalista F F Hallek M M Hillmen P P Montserrat E E Ghia P P
Leukemia 20151207 4
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy. In this European Research Initiative on CLL (ERIC) project we have identified and validated a flow-cytometric approach to reliably quantitate CLL cells to the level of 0.0010% (10(-5)). The assay com ...[more]